334 related articles for article (PubMed ID: 28339833)
1. VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties.
Arif T; Krelin Y; Nakdimon I; Benharroch D; Paul A; Dadon-Klein D; Shoshan-Barmatz V
Neuro Oncol; 2017 Jul; 19(7):951-964. PubMed ID: 28339833
[TBL] [Abstract][Full Text] [Related]
2. Reducing VDAC1 expression induces a non-apoptotic role for pro-apoptotic proteins in cancer cell differentiation.
Arif T; Krelin Y; Shoshan-Barmatz V
Biochim Biophys Acta; 2016 Aug; 1857(8):1228-1242. PubMed ID: 27080741
[TBL] [Abstract][Full Text] [Related]
3. Rewiring of Cancer Cell Metabolism by Mitochondrial VDAC1 Depletion Results in Time-Dependent Tumor Reprogramming: Glioblastoma as a Proof of Concept.
Arif T; Stern O; Pittala S; Chalifa-Caspi V; Shoshan-Barmatz V
Cells; 2019 Oct; 8(11):. PubMed ID: 31661894
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial VDAC1-based peptides: Attacking oncogenic properties in glioblastoma.
Shteinfer-Kuzmine A; Arif T; Krelin Y; Tripathi SS; Paul A; Shoshan-Barmatz V
Oncotarget; 2017 May; 8(19):31329-31346. PubMed ID: 28412744
[TBL] [Abstract][Full Text] [Related]
5. Mitochondria and nucleus cross-talk: Signaling in metabolism, apoptosis, and differentiation, and function in cancer.
Shteinfer-Kuzmine A; Verma A; Arif T; Aizenberg O; Paul A; Shoshan-Barmaz V
IUBMB Life; 2021 Mar; 73(3):492-510. PubMed ID: 33179373
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated States.
Arif T; Paul A; Krelin Y; Shteinfer-Kuzmine A; Shoshan-Barmatz V
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30544833
[TBL] [Abstract][Full Text] [Related]
7. The Mitochondrial Protein VDAC1 at the Crossroads of Cancer Cell Metabolism: The Epigenetic Link.
Amsalem Z; Arif T; Shteinfer-Kuzmine A; Chalifa-Caspi V; Shoshan-Barmatz V
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331482
[TBL] [Abstract][Full Text] [Related]
8. ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics.
Xu Q; Hu C; Zhu Y; Wang K; Lal B; Li L; Tang J; Wei S; Huang G; Xia S; Lv S; Laterra J; Jiang Y; Li Y
Cancer Lett; 2020 Jul; 482():126-135. PubMed ID: 31954770
[TBL] [Abstract][Full Text] [Related]
9. The mitochondrial voltage-dependent anion channel 1 in tumor cells.
Shoshan-Barmatz V; Ben-Hail D; Admoni L; Krelin Y; Tripathi SS
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2547-75. PubMed ID: 25448878
[TBL] [Abstract][Full Text] [Related]
10. Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor Hallmarks.
Pandey SK; Machlof-Cohen R; Santhanam M; Shteinfer-Kuzmine A; Shoshan-Barmatz V
Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883451
[TBL] [Abstract][Full Text] [Related]
11. Silencing the Mitochondrial Gatekeeper VDAC1 as a Potential Treatment for Bladder Cancer.
Alhozeel B; Pandey SK; Shteinfer-Kuzmine A; Santhanam M; Shoshan-Barmatz V
Cells; 2024 Apr; 13(7):. PubMed ID: 38607066
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Reprograming Via Silencing of Mitochondrial VDAC1 Expression Encourages Differentiation of Cancer Cells.
Arif T; Amsalem Z; Shoshan-Barmatz V
Mol Ther Nucleic Acids; 2019 Sep; 17():24-37. PubMed ID: 31195298
[TBL] [Abstract][Full Text] [Related]
13. ZWINT: A potential therapeutic biomarker in patients with glioblastoma correlates with cell proliferation and invasion.
Yang L; Han N; Zhang X; Zhou Y; Chen R; Zhang M
Oncol Rep; 2020 Jun; 43(6):1831-1844. PubMed ID: 32323832
[TBL] [Abstract][Full Text] [Related]
14. Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma.
Kang H; Lee S; Kim K; Jeon J; Kang SG; Youn H; Kim HY; Youn B
J Exp Clin Cancer Res; 2021 Sep; 40(1):282. PubMed ID: 34488821
[TBL] [Abstract][Full Text] [Related]
15. Lipid metabolism enzyme ACSVL3 supports glioblastoma stem cell maintenance and tumorigenicity.
Sun P; Xia S; Lal B; Shi X; Yang KS; Watkins PA; Laterra J
BMC Cancer; 2014 Jun; 14():401. PubMed ID: 24893952
[TBL] [Abstract][Full Text] [Related]
16. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
17. A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1.
Lee JS; Xiao J; Patel P; Schade J; Wang J; Deneen B; Erdreich-Epstein A; Song HR
Neuro Oncol; 2014 Jan; 16(2):191-203. PubMed ID: 24305710
[TBL] [Abstract][Full Text] [Related]
18. Selective induction of cancer cell death by VDAC1-based peptides and their potential use in cancer therapy.
Shteinfer-Kuzmine A; Amsalem Z; Arif T; Zooravlov A; Shoshan-Barmatz V
Mol Oncol; 2018 Jun; 12(7):1077-1103. PubMed ID: 29698587
[TBL] [Abstract][Full Text] [Related]
19. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma.
Crommentuijn MH; Maguire CA; Niers JM; Vandertop WP; Badr CE; Würdinger T; Tannous BA
Mol Oncol; 2016 Apr; 10(4):625-34. PubMed ID: 26708508
[TBL] [Abstract][Full Text] [Related]
20. LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program.
Mao XG; Hütt-Cabezas M; Orr BA; Weingart M; Taylor I; Rajan AK; Odia Y; Kahlert U; Maciaczyk J; Nikkhah G; Eberhart CG; Raabe EH
Oncotarget; 2013 Jul; 4(7):1050-64. PubMed ID: 23846349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
